论文部分内容阅读
本文中老年肺癌患者红细胞中Cu·Zn-SOD活性进行测定,结果表明,肺癌组SOD活性(1358±339U/gHb)明显低于肺部良性疾病组(1504±198U/gHb)和健康对照组(1577±208U/gHb)(P<0.05和P<0.01);临床治疗对其生物活性的影响曲线显示,在年龄水平相同时,健康组、肺部良性疾病组、肺癌未疗组、放疗组、化疗组中SOD活性依次呈递减趋势;而肺癌未疗组、术疗组、合疗组SOD活性呈依次递增趋势。合疗组SOD活性呈直线上升趋势,其均值(1821±257U/gHb)在上述八个组中最大,并明显超过健康对照组水平。提示肺癌的发生、发展和变化过程,自由基和SOD改变是其重要机制,且临床治疗对其生物活性产生明显影响。
The activity of Cu·Zn-SOD in erythrocytes of elderly patients with lung cancer was determined in this study. The results showed that the SOD activity (1358±339 U/gHb) in the lung cancer group was significantly lower than that in the benign lung disease group (1504±198 U/gHb) and healthy control group ( 1577 ± 208 U/gHb) (P <0.05 and P <0.01); clinical treatment of its biological activity curve showed that at the same age level, healthy group, lung benign disease group, lung cancer untreated group, radiotherapy group, The activities of SOD in the chemotherapy group showed a decreasing trend sequentially, while the activities of SOD in the untreated group, the treatment group, and the combined treatment group showed an increasing trend. The SOD activity in the combination therapy group showed a linear upward trend, and the mean value (1821±257 U/gHb) was the largest among the above eight groups and was significantly higher than that of the healthy control group. It suggests that the occurrence, development and change of lung cancer, free radicals and SOD changes are important mechanisms, and clinical treatment has a significant impact on its biological activity.